bg_top_pipeline.png

IMB002

IMB002
img_imb002.jpg

IMB002, the company’s patented strain, is a new live biotherapeutic candidate with unique polysaccharides, called CSGG, on the surface.

Inhibition of inflammatory responses

img_imb001_01.png

These polysaccharides with the unique structure of CSGG induce regulatory dendritic cells (rDC), which in turn induce Treg, immune regulatory cells, inhibiting the production of IFNr, an inflammatory cytokine while facilitating the secretion of IL-10, an anti-inflammatory cytokine, thus inhibiting inflammatory reaction.